Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Study of Pimicotinib in Japanese Participants with Tenosynovial Giant Cell Tumor
jRCT2071250149Phase 2Recruiting
- Sponsor
- Merck KGaA
- Start
- Apr 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of pimicotinib in tenosynovial giant cell tumor (TGCT) (2 cohorts), sponsored by Merck KGaA. Primary endpoints: Number of Participants with Dose Limiting Toxicity (DLT)-like events, Pharmacokinetic Plasma Concentration of Pimicotinib and 1 more. Started Apr 2026; status: recruiting.
02
Drugs
pimicotinib
03
Conditions
tenosynovial giant cell tumor (TGCT)
Beyond the preview
Go deeper on jRCT2071250149.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2071250149.